文献速递白血病淋巴瘤浆细胞疾病

接种疫苗的癌症患者突破性COVID-19感染的风险与结局:来自美国国家COVID队列协作组的真实世界证据

Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.
PubMed 文献 · J Clin Oncol · 2022-03-14

该研究利用美国国家COVID队列协作组(N3C)数据,分析2020年12月1日至2021年5月31日期间接种mRNA疫苗后发生突破性感染的患者,共识别6,860例突破性感染,其中1,460例(21.3%)为癌症患者。实体瘤和血液恶性肿瘤患者突破性感染风险及严重结局风险均显著高于非癌症患者,血液恶性肿瘤风险高于实体瘤。

要点

  • 实体瘤和血液恶性肿瘤患者突破性感染风险均显著高于非癌症患者。
  • 血液恶性肿瘤患者突破性感染风险高于实体瘤患者。
  • 第二剂疫苗后所有癌症患者突破性感染风险降低。

核心结论

  • 真实世界证据显示,癌症患者尤其是血液恶性肿瘤患者发生突破性感染和严重结局的风险更高。
  • 接种疫苗的患者突破性感染风险显著降低。
  • 需要进一步研究评估加强针和新型SARS-CoV-2变异株。

研究设计与样本

  • 利用美国国家COVID队列协作组(N3C)识别2020年12月1日至2021年5月31日期间的突破性感染。
  • 纳入部分或完全接种mRNA COVID-19疫苗且无既往SARS-CoV-2感染记录的患者。
  • 采用逻辑回归分析突破性感染和严重结局的风险。

主要发现

  • 在N3C接种疫苗人群中识别出6,860例突破性感染,其中1,460例(21.3%)为癌症患者。
  • 调整年龄、性别、种族/ ethnicity、吸烟状态、疫苗类型和接种日期后,实体瘤和血液恶性肿瘤患者突破性感染风险均显著高于非癌症患者(OR=1.12,95% CI 1.01-1.23;OR=4.64,95% CI 3.98-5.38)。
  • 实体瘤和血液恶性肿瘤患者严重结局风险均显著高于非癌症患者(OR=1.33,95% CI 1.09-1.62;OR=1.45,95% CI 1.08-1.95)。
  • 与实体瘤相比,血液恶性肿瘤患者突破性感染风险增加(调整OR从淋巴瘤的2.07到淋巴细胞白血病的7.25)。
  • 所有癌症患者第二剂疫苗后突破性感染风险降低(OR=0.04;95% CI 0.04-0.05),Moderna mRNA-1273疫苗较Pfizer BNT162b2疫苗突破性感染风险降低(OR=0.66;95% CI 0.62-0.70),尤其在多发性骨髓瘤患者中(OR=0.35;95% CI 0.15-0.72)。

局限性

  • 需要进一步研究评估加强针和新型SARS-CoV-2变异株。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide real-world evidence on risks and outcomes of breakthrough COVID-19 infections in vaccinated patients with cancer using the largest national cohort of COVID-19 cases and controls. METHODS: We used the National COVID Cohort Collaborative (N3C) to identify breakthrough infections between December 1, 2020, and May 31, 2021. We included patients partially or fully vaccinated with mRNA COVID-19 vaccines with no prior SARS-CoV-2 infection record. Risks for breakthrough infection and severe outcomes were analyzed using logistic regression. RESULTS: A total of 6,860 breakthrough cases were identified within the N3C-vaccinated population, among whom 1,460 (21.3%) were patients with cancer. Solid tumors and hematologic malignancies had significantly higher risks for breakthrough infection (odds ratios [ORs] = 1.12, 95% CI, 1.01 to 1.23 and 4.64, 95% CI, 3.98 to 5.38) and severe outcomes (ORs = 1.33, 95% CI, 1.09 to 1.62 and 1.45, 95% CI, 1.08 to 1.95) compared with noncancer patients, adjusting for age, sex, race/ethnicity, smoking status, vaccine type, and vaccination date. Compared with solid tumors, hematologic malignancies were at increased risk for breakthrough infections (adjusted OR ranged from 2.07 for lymphoma to 7.25 for lymphoid leukemia). Breakthrough risk was reduced after the second vaccine dose for all cancers (OR = 0.04; 95% CI, 0.04 to 0.05), and for Moderna's mRNA-1273 compared with Pfizer's BNT162b2 vaccine (OR = 0.66; 95% CI, 0.62 to 0.70), particularly in patients with multiple myeloma (OR = 0.35; 95% CI, 0.15 to 0.72). Medications with major immunosuppressive effects and bone marrow transplantation were strongly associated with breakthrough risk among the vaccinated population. CONCLUSION: Real-world evidence shows that patients with cancer, especially hematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes. Patients with vaccination were at markedly decreased risk for breakthrough infections. Further work is needed to assess boosters and new SARS-CoV-2 variants.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Song Q, Bates B, Shao YR, et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative. J Clin Oncol. 2022. PMID: 35286152. doi:10.1200/JCO.21.02419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。